E Fund Management Co., Ltd. Fate Therapeutics Inc Transaction History

E Fund Management Co., Ltd.

$1.93 Billion
Q3 2024

A detailed history of E Fund Management Co., Ltd. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 353,771 shares of FATE stock, worth $587,259. This represents 0.06% of its overall portfolio holdings.

Number of Shares

353,771

Previous 355,225 0.41%

Holding current value

$587,259

Previous $1.17 Million 6.27%

% of portfolio

0.06%

Previous 0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.12 - $5.57 $4,536 - $8,098	-1,454 Reduced 0.41%	353,771 $1.24 Million
Q2 2024 Aug 12, 2024	BUY	$3.26 - $7.08 $1.05 Million - $2.27 Million	320,745 Added 930.23%	355,225 $1.17 Million
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $122,059 - $287,908	34,480 New	34,480 $253,000
Q2 2023 Aug 11, 2023	SELL	$4.76 - $6.59 $132,266 - $183,116	-27,787 Reduced 35.11%	51,350 $244,000
Q1 2023 May 11, 2023	BUY	$4.24 - $11.12 $240,751 - $631,404	56,781 Added 253.99%	79,137 $451,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $53,283 - $128,777	5,404 Added 31.88%	22,356 $226,000
Q3 2022 Nov 14, 2022	SELL	$21.04 - $36.06 $108,377 - $185,745	-5,151 Reduced 23.3%	16,952 $380,000
Q2 2022 Aug 15, 2022	BUY	$17.78 - $42.39 $250,822 - $597,995	14,107 Added 176.43%	22,103 $548,000
Q1 2022 May 12, 2022	BUY	$29.67 - $60.28 $132,565 - $269,331	4,468 Added 126.64%	7,996 $310,000
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $98,215 - $132,090	2,053 Added 139.19%	3,528 $206,000
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $106,436 - $173,165	1,475 New	1,475 $121,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.

Account

E Fund Management Co., Ltd. Fate Therapeutics Inc Transaction History